Volume 9, Issue 2 (Summer 2005)                   2005, 9(2): 20-25 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Asgary S, . Naderi G, Gharipoor M, . Khosravi A. In vitro effect of nicotine and cotinine on susceptibility of LDL to oxidation and hemoglobin glycosylation. Journal of Inflammatory Diseases. 2005; 9 (2) :20-25
URL: http://journal.qums.ac.ir/article-1-283-en.html
1- , Email : S_asgari@crc.mui.ac.ir_
Abstract:   (19276 Views)
¯Abstract Background: Nicotine, a major component of cigarette smoke, plays an important role in development of cardiovascular disease and lung cancer in smokers. Objective: This study was designed to determine the in vitro effects of nicotine and its metabolite, cotinine on the susceptibility of LDL to oxidation and hemoglobin glycosylation. Methods: Three different concentrations of each component (10,15,25µg/ml) were used. The glycosylation rate of hemoglobin in the presence and absence of nicotine and cotinine were measured by colorimetric method. The susceptibility of LDL to in vitro oxidation was assessed by the Regnstrom technique. Findings: Our data showed that nicotine and cotinine are inhibitors for Cu2+-induced LDL oxidation but also increased the glycosylation rate of hemoglobin. Nicotine at final concentrations of (10, 15, and 25μg/ml) increased the rate of hemoglobin glycosylation by 25%, 32% and 47%, respectively. Cotinine at similar concentrations, also increasd the rate of glycosylation by 8, 10 and 12%, respectively. Conclusion: Based on data obtained in our study, smoking can result in higher levels of hemoglobin glycosylation which in turn increases the risk of cardiovascular diseases.
Full-Text [PDF 149 kb]   (2652 Downloads)    
Type of Study: Research | Subject: Cardiology

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Inflammatory Diseases

Designed & Developed by : Yektaweb